LTR Pharma (ASX:LTP) Inventories, Finished Goods: A$0.00 Mil (As of Dec. 2025)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.54
View Full Analysis

What is LTR Pharma Inventories, Finished Goods?

LTR Pharma ASX:LTP +0.93% 15 Inventories, Finished Goods is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100.

LTR Pharma Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Inventories, Finished Goods Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Inventories, Finished Goods
0.00 0.00 0.00 0.00 0.00

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Finished Goods Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of A$0.00 Mil mean?
LTR Pharma (ASX:LTP) has a Inventories, Finished Goods of A$0.00 Mil as of Dec. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on LTR Pharma and its competitors.
Is LTR Pharma's Inventories, Finished Goods too high?
LTR Pharma's current Inventories, Finished Goods is A$0.00 Mil. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Inventories, Finished Goods compare to VRTX and REGN?
LTR Pharma's Inventories, Finished Goods of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on LTR Pharma and its competitors. LTR Pharma's current Inventories, Finished Goods is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Inventories, Finished Goods of A$0.00 Mil. The current Inventories, Finished Goods is A$0.00 Mil. LTR Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Inventories, Finished Goods is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.54
Price